A London-based startup focused on regenerative medicine has secured new investment from a high-profile venture capital firm. The investor, recognized for early-stage support of major British technology companies such as Deliveroo and Darktrace, is backing the firm’s efforts to advance medical technology capable of regrowing human tooth enamel and bone.

While the specific financial terms of the investment have not been publicly disclosed, the move marks a strategic shift for the backer toward the biotechnology sector. The startup’s proprietary process aims to address common dental and skeletal issues by stimulating natural tissue regeneration, a field that has seen increased interest from venture capital firms looking for long-term medical breakthroughs. The investment is expected to accelerate the company's research and development phase as it moves toward clinical validation of its regeneration technology.